Guo Jinyu, Liu Changhua, Qi Zhaoyang, Qiu Ting, Zhang Jin, Yang Huanghao
Qingyuan Innovation Laboratory, 1 Xueyuan Road, Quanzhou, 362801, PR China.
College of Chemical Engineering, Fuzhou University, 2 Xueyuan Road, Fuzhou, 350108, PR China.
Bioact Mater. 2024 Mar 10;36:330-357. doi: 10.1016/j.bioactmat.2024.02.028. eCollection 2024 Jun.
Nanovaccines have gathered significant attention for their potential to elicit tumor-specific immunological responses. Despite notable progress in tumor immunotherapy, nanovaccines still encounter considerable challenges such as low delivery efficiency, limited targeting ability, and suboptimal efficacy. With an aim of addressing these issues, engineering customized nanovaccines through modification or functionalization has emerged as a promising approach. These tailored nanovaccines not only enhance antigen presentation, but also effectively modulate immunosuppression within the tumor microenvironment. Specifically, they are distinguished by their diverse sizes, shapes, charges, structures, and unique physicochemical properties, along with targeting ligands. These features of nanovaccines facilitate lymph node accumulation and activation/regulation of immune cells. This overview of bespoke nanovaccines underscores their potential in both prophylactic and therapeutic applications, offering insights into their future development and role in cancer immunotherapy.
Bioact Mater. 2024-3-10
J Control Release. 2022-11
Adv Healthc Mater. 2024-5
J Nanobiotechnology. 2022-7-26
J Nanobiotechnology. 2023-7-7
Acta Biomater. 2023-11
Bioact Mater. 2025-6-30
Theranostics. 2025-2-10
Signal Transduct Target Ther. 2025-2-21
Cancer Chemother Pharmacol. 2025-1-4
Nanomaterials (Basel). 2024-9-13
Signal Transduct Target Ther. 2023-12-16
Int J Nanomedicine. 2023
Nat Commun. 2023-11-4
Nano Lett. 2023-9-13